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AbstrACt
Introduction Systemic sclerosis (SSc) is an autoimmune 
disease characterised by inflammation, fibrosis and 
vasculopathy. Digital ulcers (DUs) are a frequent 
manifestation of vasculopathy in patients with SSc. 
Despite recent advances in pharmacological treatments, 
DU still have major health and economic implications. 
As there is currently no proven therapeutic strategy 
to promote DU healing, new treatments are urgently 
needed. Mesenchymal stem or stromal cells (MSCs) may 
provide a novel therapy for DU in SSc, because of their 
immunomodulatory and vasculoregenerative properties. 
Allogeneic MSC therapy involves functionally competent 
MSCs from healthy donors and may be used as ‘off-
the-shelf’ available treatment. This study will evaluate 
whether allogeneic MSC therapy is a safe and potentially 
efficacious treatment for DU of SSc.
Methods and analysis The MANUS (Mesenchymal 
stromal cells for Angiogenesis and Neovascularization in 
digital Ulcers of Systemic Sclerosis) Trial is a double-blind 
randomised placebo-controlled trial. 20 patients with SSc 
with refractory DU will be randomised to receive eight 
intramuscular injections with either placebo or 50*106 
MSCs. The primary outcome is the toxicity of the treatment 
at 12 weeks after administration. Secondary outcomes 
include (serious) adverse events, number and time to 
healing of DU, pain, reported hand function, quality of life 
and SSc disease activity. We will also evaluate changes 
in nailfold capillaroscopy pattern, as well as biochemical 
parameters and biomarkers in peripheral blood and skin 
biopsies. Follow-up visits will be scheduled at 48 hours 
and 2, 4, 8, 12, 24 and 52 weeks post-treatment. If the 
results confirm safety, feasibility and potential efficacy, a 
large multicentre randomised controlled trial with longer 
follow-up will be initiated focusing on efficacy.
Ethics and dissemination The study has been approved 
by the Dutch Central Committee on Research Concerning 
Human Subjects (protocol no: NL51705.000.15). The 
results will be disseminated through patient associations 
and conventional scientific channels.
trial registration number NCT03211793; Pre-results. 
IntroduCtIon 
Systemic sclerosis (SSc) is a rare multisystem 
autoimmune connective tissue disease 
with high morbidity and mortality. The 
exact aetiology and pathogenesis of SSc are 
unknown, but involve small-vessel vasculop-
athy, immune dysregulation with production 
of autoantibodies and progressive fibrosis 
of the skin and major internal organs. This 
contributes to a 10-year mortality of ~30%.1 
Microvascular vasculopathy occurs early in 
the pathogenesis of SSc.2 Such vasculopathy 
can be found in many organs, contributes to 
end-organ damage and may give rise to severe 
complications. Skin vasculopathy results in 
chronic tissue hypoperfusion and hypoxia, 
and ultimately ischaemic manifestations such 
as digital ulcers.
strengths and limitations of this study
 ► The MANUS Trial is the first double-blind randomised 
controlled trial to assess the safety and potential 
efficacy of mesenchymal stromal cells (MSCs)  for 
digital ulcers.
 ► Intramuscular injection protocol to maximise safety.
 ► Results can inform effect size and sample size con-
siderations for future trials using MSCs.
 ► Low sample size of this pilot trial requires larger fol-
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Digital ulcers are a serious problem in SSc, occurring in 
30% to 50% of patients with SSc.3 4 These ulcers are very 
painful and heal slowly with scarring and digital resorp-
tion, which causes substantial functional disability.5 6 Infec-
tions in ulcers may also occur and can lead to gangrene 
and amputation of the extremities.7 Unfortunately, the 
available treatment options do not increase ulcer healing 
or are not effective in a significant proportion of patients.
The European League Against Rheumatism guideline 
recommends intravenous iloprost, bosentan or phos-
phodiesterase-5 inhibitors (PDE-5i) for the manage-
ment of patients with digital ulcerations.8 Intravenous 
iloprost, the first-line treatment for digital ischaemia in 
SSc, has been shown to reduce ulcers by 50% in at most 
28% of treated patients in a randomised placebo-con-
trolled trial.9 Bosentan, an endothelin-1 receptor antag-
onist, has been shown to reduce new ulcer occurrence 
in two double-blind placebo-controlled trials,10 11 but no 
effect on ulcer healing has been reported so far, apart 
from a ‘trend toward efficacy’ in a small uncontrolled 
trial.12 Similarly, while PDE-5i have shown promising 
results in healing digital ulcers, in a recent double-blind 
randomised controlled trial (RCT), 18% of the patients 
in the PDE-5i arm did not show ulcer healing.13
The lack of curative options for patients with digital 
ulcers underscores the urgent clinical need for a novel, 
targeted treatment that reduces vascular complications 
and inflammation, halts fibrosis and prevents disease 
progression.14 15
Mesenchymal stem—or stromal—cells (MSCs) may be 
an effective treatment for digital ulcers caused by SSc, as 
MSCs have potent vasculoregenerative and immunomod-
ulatory properties. MSCs are a subpopulation of bone 
marrow cells that can differentiate into various mesen-
chymal cell types (chondrocytes, osteocytes, adipocytes) 
under specific in vitro conditions.16 In vitro and in vivo 
studies have demonstrated that intramuscular administra-
tion of MSCs improves wound healing through promo-
tion of angiogenesis and modulation of the locoregional 
immune response. Studies in mice demonstrated that 
intramuscular injected MSCs improve neovascularisation 
after ablation of the femoral artery (hind limb ischaemia 
model).17 MSCs were shown in vivo to secrete vascular 
endothelial growth factor, basic fibroblast growth factor 
and other cytokines, growth factors and chemokines in 
the murine hind limb ischaemia model, showing that 
MSCs are capable of paracrine interaction with a wide 
range of cells: immune cells, fibroblasts, endothelial 
cells and so on.18 19 Further in vitro studies have identi-
fied direct cell-to-cell interactions between MSCs, local 
tissue cells and various immune cells which potentiate the 
action of MSC-secreted factors.20–25 In vivo administration 
of MSCs leads to increased recruitment of macrophages 
and endothelial cells, and a reduction of effector T cells, 
suggesting possible mechanisms of action for the angio-
genic and regenerative properties of MSCs.26–28
Subsequent small randomised placebo-controlled clin-
ical trials in critical limb ischaemia showed favourable 
results of intramuscular autologous bone marrow-derived 
MSC therapy compared with standard care in patients 
with non-healing ulcers.29 30 MSC injection was more 
effective than mononuclear cell (MNCs) injection in crit-
ical limb ischaemia and non-healing ulcers of patients 
with diabetes, which confirms results from preclinical 
studies.31 32
Administration of allogeneic MSC was also effective in 
critical limb ischaemia and no treatment-related adverse 
events were observed. Intramuscular injection of alloge-
neic umbilical cord blood-derived MSC in four patients 
with limb ischaemia related to Buerger’s disease led to 
increased capillary formation and reduction in pain. 
There were no adverse events.33 In a randomised place-
bo-controlled trial using allogeneic MSCs as treatment 
for critical limb ischaemia, an increase in ankle-bra-
chial index and ankle pressure in the group treated with 
MSCs was seen. There were no treatment-related adverse 
events.34
Though there is considerable heterogeneity in the used 
cell types and administration protocols, these clinical 
studies in critical limb ischaemia suggest that injection of 
cell depots in patients with SSc may be a viable possible 
treatment for digital ulcers caused by SSc. Small uncon-
trolled studies in SSc show that injection of various autol-
ogous cells was well tolerated and did not lead to adverse 
events; however, local administration of cultured MSCs 
has not yet been assessed in this condition.35 Interestingly, 
two case reports that describe intravenous administration 
of respectively autologous or allogeneic MSCs report a 
marked effect on ulcer healing, reduction of skin fibrosis 
and promotion of new vessel formation. There were no 
adverse events associated with MSC administration.36 37 In 
addition to the studies in critical limb ischaemia and SSc, 
the safety and efficacy of allogeneic MSC administration 
has been established in a variety of conditions, including 
autoimmune disease. No acute or chronic local tissue 
reactions to the allogeneic cells have been reported.38–41 
Consequently, there are no safety concerns that would 
preclude a clinical trial that assesses allogeneic MSCs as 
a treatment option for refractory digital ulcers in SSc. 
However, the safety and feasibility of intramuscularly 
injected MSCs in SSc should be confirmed before initia-
tion of a larger trial that is sufficiently powered to assess 
efficacy is possible. Therefore, the next logical step in the 
development of a treatment option for SSc is to assess 
the safety, feasibility and possible efficacy of intramus-
cular administration of allogeneic MSCs in a randomised, 
placebo-controlled, double-blind fashion.
Here, we describe the protocol and the rationale for 
the MANUS (Mesenchymal stromal cells for Angiogen-
esis and Neovascularization in digital Ulcers of Systemic 
Sclerosis) Trial. The MANUS Trial is an investigator-initi-
ated phase IIa/b randomised placebo-controlled double-
blind trial, in which we will evaluate the safety, feasibility 
and potential efficacy of intramuscular administration of 
allogeneic MSCs as treatment for digital ulcers caused 
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potential beneficial effects of the intervention regarding 
clinical parameters, a large multicentre RCT with longer 
follow-up will be initiated focusing on efficacy.
MEthods And AnAlysIs
design
The MANUS Trial is a phase IIa/b randomised double-
blind placebo-controlled trial.
We will include 20 patients with SSc who satisfy the inclu-
sion criteria (table 1). Inclusion and exclusion criteria 
were designed to select patients with refractory ulcers 
who are in a reasonable health condition to allow trial 
participation. Study participants will be recruited from 
our own SSc outpatient population as well as in collabora-
tion with other scleroderma expert centres, who will refer 
patients to the University Medical Center Utrecht. Base-
line characteristics will be collected, including parameters 
that were shown to predict ulcer healing in observational 
cohorts,42 43 as well as skin scoring and capillaroscopy 
to assess severity and stage of SSc. A safety assessment 
including physical examination, laboratory studies, ECG 
and urine evaluation will be performed (see table 2 and 
figure 1). We anticipate to be able to commence enrol-
ment in November 2018.
Participants will be randomised in blocks by the Depart-
ment of Clinical Pharmacy using a computerised table, 
with the block size unknown to the investigators. The 
treatment allocation will be implemented by the Cell 
Therapy Facility, with no communication of allocation 
status to the investigational team. Both investigators and 
participants will be blinded to treatment allocation by the 
use of a verum and a placebo product that are similar in 
appearance. In case of an emergency, deblinding can be 
performed by the Department of Pharmacy.
The inclusion of a placebo control arm in the design 
of the MANUS Trial despite the relatively low number 
is important to properly evaluate feasibility, safety 
and secondary efficacy outcomes. A two-armed design 
will enable us to assess whether patients are willing to 
participate if a placebo arm is present. The possibility of 
randomisation can have a major impact on participant 
accrual; for instance, in the reJUVenating ENdothe-
lial progenitor cells via Transcutaneous intra-Arterial 
Supplementation (JUVENTAS trial), one-third of poten-
tially eligible patients was excluded due to unwilling-
ness to participate in a randomised trial, even though 
this represented a ‘no option’ population who had no 
other alternatives than conservative management or 
amputation.44
Many of the secondary efficacy outcomes and some of 
the safety outcomes in the proposed study incorporate 
a degree of subjectivity and are therefore subject to bias 
from both patients and assessors. Given the considerable 
placebo effect that can be observed in trials assessing 
‘stem cell treatments’, blinding of both clinicians as well 
as participants is of paramount importance. For instance, 
in MNC therapy for cardiac disease, early uncontrolled 
trials showed an effect, whereas later, more rigorously 
designed RCTs did not show an effect, despite the rela-
tively robust outcome measures used.45
Additionally, we will be able to determine whether the 
used blinding procedures are effective at masking treat-
ment allocation. No such formal evaluation exists for 
intramuscular placebo injections of a cellular product in 
contrast to pharmacological placebos, which are much 
better characterised.
Ethical concerns of stem cell therapy due to subjecting 
the placebo group to an invasive sham procedure were 
previously explored by our group.46 The risk of compli-
cations is considered to be very low, based on studies that 
already explored intramuscular administration of MSCs 
in various settings as described previously. Should compli-
cations arise, the placebo control will help attributing 
these to the MSC product or the intramuscular injections 
per se. Furthermore, as there is no alternative treatment 
for patients with digital ulcers refractory to intravenous 
prostanoids, patients are not withheld regular care. 
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Ulcer with underlying 
calcinosis (ruled out by 
X-ray prior to screening/
inclusion)
Age >18 years History of neoplasm or 
malignancy in the past 
10 years
Established diagnosis of SSc 
according to the 2013 ACR/EULAR 
criteria
Pregnancy or unwillingness 
to use adequate 
contraception during study
At least one active digital ulcer 
(painful area, >2 mm in diameter 
with visible depth and loss of 
dermis) refractory to intravenous 
prostacyclins:
 ► Refractory to prostacyclins is 
defined as
 – Worsening of ulcer(s) within 
1 month after intravenous 
prostacyclins
 – No improvement of ulcer(s) 
after 2 months after 
intravenous prostacyclins, 
as judged by the referring 
physician
 – Recurrence of exactly the 
same ulcer(s) (same location) 
within 3 months after 
intravenous prostacyclins
Serious known 
concomitant disease with 
life expectancy <1 year
Written informed consent Uncontrolled hypertension
Uncontrolled acute or 
chronic infection with 
systemic symptoms (eg, 
fever)
Follow-up impossible
ACR, American College of Rheumatology; EULAR, European 
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There are also no restrictions on the treatment patients 
may receive prior to participation.
Intervention
Investigational medicinal product
In this study, allogeneic MSCs will be used. Use of autol-
ogous cells seems preferable for immunological reasons, 
as enhanced clearance of allogeneic cells has been 
suggested, possibly through formation of alloreactive 
antibodies.47 However, the use of autologous cells may 
have disadvantages, as MSCs obtained from patients with 
SSc may have reduced vasculoregenerative properties 
and may have been affected by disease. SSc MSCs display 
a different phenotype compared with MSCs from healthy 
controls and have a reduced capacity to differentiate 
into endothelial cells.48 49 MSCs from patients with SSc 
also overexpress proangiogenic and profibrotic factors.50 
They also express more transforming growth factor 
beta (TGF-β) type II receptors and produce more 
collagen-α2 mRNA on TGF-β  stimulation, a pathway 
implicated in the development of fibrosis.51 Preclinical 
studies with timed chemotherapeutic ablation of MSCs 
have shown that permanent integration of MSCs is not 
required for sustained therapeutic effects.52 In a patient 
population where aberrant fibroblastic differentiation 
and fibrosis are theoretical risks, enhanced clearance of 
the allograft are likely even desirable. Lastly, the use of 
autologous MSCs requires bone marrow aspiration and 
cell culture, which is an additional burden for the patient, 
increases costs and delays treatment.53
The MSCs to be used in this study (product name: 
MSC, marrow) are harvested from bone marrow donated 
by voluntary donors. Donors are screened for infectious 
diseases as indicated by the Wet Veiligheid en Kwaliteit 
Lichaamsmaterialen, the transposition into Dutch law 
of the European Union directive 2006/17. MSCs are 
expanded and processed by the University Medical Center 
Utrecht Good Manufacturing Practice (GMP) certi-
fied Cell Therapy Facility. After harvesting, the cells are 
expanded ex vivo in alpha-minimum essential medium 
containing 5% human platelet lysate. Before release, the 
product is tested for bacterial/fungal contamination and 
Table 2 SPIRIT schedule of study visits and study procedures
Baseline Week 0 48 hours Week 2 Week 4 Week 8 Week 12 Week 24 Week 52
Informed consent x
mRSS x x x x
Pictures of hands x x x x x x x x x
Questionnaires x x x x
H&P x x x x x x x x
Safety laboratory studies x x x
Biomarker laboratory x x x x x
Skin biopsy x x
Urine screening x x x
Capillaroscopy x x x x x
ECG x x
Administration of allocated 
treatment
x
Monitoring of adverse events x x x x x x x x
H&P, history and physical examination; mRSS, modified Rodnan Skin Score; SPIRIT, Standard Protocol Items: Recommendations for 
Interventional Trials. 
Figure 1 CONSORT study flow diagram of the MANUS 
Trial. See table 2 for the schedule of study visits and 
the assessments conducted at each visit. CONSORT, 
Consolidated Standards of Reporting Trials; IM, 
intramuscular; MANUS, Mesenchymal stromal cells for 
Angiogenesis and Neovascularization in digital Ulcers of 
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endotoxins. MSCs were expanded ex vivo until passage 
3 and cryopreserved until use. Cells from two different 
donors will be used. The product to be administered to 
patients will be thawed on the day of treatment, washed 
to remove the cryopreservant dimethyl sulfoxide and 
resuspended in NaCl 0.9% containing 10% human serum 
albumin. The placebo will consist of NaCl 0.9% and 10% 
human serum albumin. Syringes will be blinded.
Route of administration and injection sites
The intramuscular route for MSC administration will be 
used. Currently, there are no clinical studies in upper 
limb ischaemia that compare the safety and efficacy of 
the various administration routes and locations. However, 
there are indications that intramuscular administration is 
superior to intravascular administration.
First, in patients with vascular complications of SSc, the 
peripheral perfusion is compromised by the very nature 
of their disease. Intramuscular administration bypasses 
this problem altogether by delivering the cells closer to 
the ulcer site. Second, muscle tissue supports intramuscu-
lar-injected MSCs with nutrients and oxygen, which bene-
fits the survival and in vivo functions of MSC.54 Thirdly, 
intramuscular injection may also be safer in patients with 
SSc, as intravenous administration in both preclinical and 
clinical studies has been shown to lead to entrapping of 
MSCs in the lungs.55 56 While no pulmonary embolism 
or other pulmonary pathology were reported in clinical 
studies conducted so far, pulmonary trapping of MSC 
seems less desirable in a patient population at risk for 
pulmonary pathology, such as patients with SSc.
Previous preclinical and clinical studies using the intra-
muscular route, in which MSC were administered as treat-
ment for patients with critical limb ischaemia and/or 
non-healing ulcers, show that the treatment was well-tol-
erated and there was no evidence for local or systemic 
toxicity, as we discussed above.17 31 33 34 Additionally, a 
number of clinical studies using cellular products for 
critical limb ischaemia in the upper limb have applied 
the intramuscular administration route with success.57–59
Clinical studies in patients with ischaemia or ulcers of 
the lower extremity in which cells were injected intramus-
cularly report injection sites both close to and at a distance 
from the ulcers. Only very few studies reported on local 
injections in the upper extremity and protocols differed 
widely with regard to the location and the number of 
injections. On assessing these protocols, we found that in 
some instances it can be questioned whether these were 
true intramuscular injections, or the injection sites were 
close to essential structures which might pose a safety 
risk, or the location would provide insufficient space to 
harbour an injected volume.
Based on the available data, the superiority of intramus-
cular MSC administration in animal models, and given 
that it is unknown which injections are most effective (at a 
distance vs local), we designed an injection protocol that 
combines both distant intramuscular injection sites as 
well as intramuscular injection sites closer to the fingers; 
2× forearm, 4× mm interossei, thenar and hypothenar 
musculature— eight injections in total (see figure 2).
Dose
Fifty million allogeneic MSCs divided in eight doses of 
0.5 mL or 1 mL (1 mL: forearm; 0.5 mL: hand injections) 
will be administered.
MSC doses in clinical trials for critical limb ischaemia 
of the lower limb ranged from 1*106 to 900*106.31 33 To 
reduce the risk of injection-related complications, we have 
decided to use fewer injection sites compared with other 
studies in which cells are injected into the upper extremity. 
This number of sites limits the amount of cells that can 
be injected. At a total dose of 50*106 cells, our dose is in 
the lower range. Animal and human studies with a dose-
finding component have previously shown that high cell 
doses do not necessarily lead to better efficacy, but even 
suggested an inverse dose–response effect. Cell crowding 
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is thought to play a role.38 54 60 The number of MSCs per 
injection in our protocol does not exceed doses used in 
literature despite the reduction of injection sites.
Supportive care and concomitant medication
Non-pharmacological therapy and patient counselling 
regarding prevention of ulcers and ulcer care will be 
provided in accordance to the Systemic Sclerosis Care 
Pathway (Zorgpad Sclerodermie) of the Dutch Rheuma-
tology Association. The need for surgical management 
will be assessed in consultation with/after evaluation by 
the hand surgeon of the trial team and in close collabora-
tion with the patient’s own rheumatologist.
We aim to avoid alterations to the medication regimen 
of patients during the trial. Drugs that can influence local 
perfusion should not be started between 4 weeks prior to 
MSC administration and 12 weeks after; dose changes are 
not allowed during this period. However, if it is deemed 
medically necessary, the medication regimen can be 
altered by the patient’s own rheumatologist. This may 
include additional iloprost infusions or other therapy 
directed to digital ulcers. Medication use, including anal-
gesic use, will be carefully documented.
outcomes and follow-up
Follow-up appointments have been scheduled to allow 
early detection of possible adverse events and optimal 
evaluation of possible MSC-mediated effects through 
biomarkers, clinical change and objective change as 
detected with capillaroscopy and physical examination. 
Follow-up will be more frequent in the first 3 months, 
with the last follow-up visit 1 year after treatment to assess 
long-term safety.
The MANUS Trial will be overseen by the Internal 
Data Safety Monitoring Board (DSMB) of the University 
Medical Center Utrecht. This is an independent DSMB, 
consisting of clinicians (including an expert on sclero-
derma), a biostatistician and a clinical epidemiologist. 
Every 3 months, the DSMB will review the status and 
conduct of the clinical trial, evaluate all causes of death 
and adverse events and make recommendations to the 
clinical research group concerning the trial’s continua-
tion and modification.
Safety
The primary outcome is the toxicity of the treatment at 12 
weeks after MSC administration, defined as
(1) local toxicity, including signs of local inflammation 
(swelling, warmth, impairment of function), worsening of 
ulcers or new ulcers or haematomas after MSC adminis-
tration and (2) other adverse events, graded according 
to the Common Terminology Criteria for Adverse Events, 
version 4.0, expressed as maximum grade toxicity per 
organ system.
Secondary safety outcomes are the incidence of any 
serious adverse events (SAEs) at 12 weeks post-treatment, 
defined as events leading to hospitalisation, death or 
persistent or significant disability.
Efficacy
Evaluation of therapies for digital ulcers has been compli-
cated by a lack of suitable outcomes.60 61 To assess poten-
tially relevant outcome measures for efficacy, we will use 
validated questionnaires for quality of life, hand function 
and detailed ulcer observations. Currently, the relation 
between the Scleroderma Health Assessment Question-
naire (S-HAQ) and other quality-of-life questionnaires 
and ulcer-related hand function is unsure—the only vali-
dated efficacy parameter for digital ulcer treatments in 
SSc is the number of ulcers and ulcer healing.62 In the 
MANUS Trial, we will therefore use these questionnaires 
to further explore the effect of digital ulcers on disability 
and quality of life.
Ulcer healing will be monitored both clinically and 
through sequential digital pictures. Pictures will be 
taken in a standardised and reproducible fashion. While 
manual measuring of ulcers has been shown to be unreli-
able, using digital pictures to measure ulcer size has been 
reported as a valid and reproducible method—digital 
pictures with a reference scale included were shown to be 
equally reliable and reproducible as tracing the ulcers on 
transparent material.63 64
Nailfold capillaroscopy (NFC) is a reproducible non-in-
vasive method to visualise the nailfold capillaries and 
assess microvascular morphology. Images will be scored 
both qualitatively as well as semiquantitatively, using stan-
dardised and previously validated methods.65 66 It has 
been shown that therapy directed to the microvascula-
ture can lead to favourable changes in the NFC pattern 
in SSc, though it is uncertain when the effects will be first 
apparent.67 68 Therefore, NFC will be conducted at 2, 12, 
24 and 52 weeks.
While the study is not powered to assess efficacy, various 
outcome measures for efficacy will be assessed to assess 
their feasibility as an outcome as well as inform future 
power calculations. These outcome measures include 
change in patients-reported ulcer pain, quality of life as 
assessed with validated questionnaires (SF-36, S-HAQ, 
EQ5D), hand function as assessed with the Cochin Hand 
Function Scale, number of digital ulcers at 12 weeks, 
healing of ulcers at 12 weeks, area of digital ulcers, the 
need to alter the medication regimen during the study 
as determined by the patient’s own rheumatologist, the 
severity of SSc as assessed with the Modified Rodnan Skin 
Score, severity of Raynaud’s symptoms, changes in capil-
lary morphology as visualised with video-assisted NFC, and 
changes in laboratory parameters including biomarkers 
for inflammation and endothelial (dys)function. Plasma, 
serum and peripheral blood MNCs will be sampled at 
baseline and 48 hours, 2, 4 and 12 weeks post-treatment, 
and a skin biopsy will be taken at baseline and at 12 weeks. 
For binary outcomes, the observed effect estimates and 
for continuous outcomes, the mean and SD can be used 
as a basis for future power calculations.
To determine which outcome would be most appro-
priate in the follow-up trial, an expert group will be 
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approach.69 For each participant, it will be established 
whether ulcers have improved in the time period between 
inclusion and the primary endpoint. This expert judge-
ment of ‘improvement’ or not will then be linked to the 
clinical outcome data that we collected within the trial. 
We will then assess whether there is a single outcome 
parameter that can define response or whether composite 
outcome would be preferred.
Feasibility
A larger trial will be deemed feasible if the treatment is 
safe, if recruitment for this trial can be completed within 
a reasonable time (12 months) and if treatment alloca-
tion can be successfully be concealed from clinicians and 
participants.
Treatment safety will be determined in close consul-
tation with the DSMB. In case of SAEs related to the 
treatment, a follow-up trial will not be commenced. To 
establish the presence of a causal relationship to the study 
treatment, the WHO guideline for pharmacovigilance 
will be followed.
The rate of recruitment and willingness to participate 
in a trial that contains a placebo arm in this pilot will 
inform our decision regarding recruitment feasibility 
for a larger trial based on the calculated sample size and 
recruitment duration. As there will only be 10 patients in 
the treatment group, we understand that the incidence of 
adverse events in this trial may be a poor estimate of the 
expected incidence in a larger trial. If, however, there are 
any serious AEs definitely attributable to the treatment 
according to the WHO guidelines for pharmacovigilance, 
we will reconsider the definitive trial or its design.
Concealment of treatment allocation will be assessed by 
asking participants and clinicians in which arm they think 
the participant was, using a three-point scale (‘verum’, 
‘placebo’ or ‘don’t know’). To gain a balanced view, this 
question will be posed at 12 weeks (primary endpoint) 
and at 52 weeks (conclusion of the trial). Data will be 
analysed using James’ and Bang’s Blinding index to deter-
mine the degree of blinding in the trial, within each arm 
and whether this deviates from random chance.70
statistical analyses
The N of 20 is based on the number of patients that we 
can realistically recruit from our own population and 
collaborating centres. This number will allow us to detect 
which, if any, SAEs may occur and will provide a rough 
estimate of effect size that may inform the design of 
future studies. To be able to determine statistically signif-
icant differences with regard to safety and efficacy, much 
larger groups will likely be needed. However, to be able 
to include such a number of patients, an international 
multicentre trial would need to be initiated. This would 
require more solid indications regarding the safety and 
potential efficacy of MSCs in SSc, as may be provided by 
the proposed study.
Data will be analysed on an intention-to-treat basis. Data 
regarding adverse events and SAEs will be provided using 
descriptive statistics and tables. Population characteristics 
will be provided using descriptive statistics. Comparisons 
between groups will be made using linear mixed models. 
For dichotomous outcomes, generalised mixed models 
or Kaplan-Meier curves and the log-rank test will be used 
where appropriate.
Patient involvement
The lack of effective treatments for digital ulcers and the 
subsequent impact on daily functioning and quality of life 
is a major unmet need for patients with SSc. Patient advo-
cacy has led to incorporation of ‘effect on digital ulcers’ 
as a required outcome measure prior to European Medi-
cines Agency registration of pharmaceuticals as treat-
ment for SSc. The exploratory outcome measures in this 
trial also include patient reported outcomes (disability, 
quality of life) to fully capture the possible effects of MSC 
administration.
A patient advocate is part of the Trial End User 
Committee, which meets once a year and includes rheu-
matology experts, regenerative medicine experts and 
intellectual property advisors. The research protocol 
and the patient letter/informed consent form has been 
discussed with this patient advocate, who is a member of 
the NVLE (Dutch association for scleroderma, systemic 
lupus and MCTD). The NVLE has kindly agreed to post 
information (which has been ethically approved prior to 
publication) about the trial on their website. The results 
of the study will be disseminated to the study participants 
through a newsletter and a patient information day. The 
burden of the intervention has not been assessed by 
patients themselves.
EthICs And dIssEMInAtIon
The study will be conducted according to the principles 
of the Declaration of Helsinki (Adopted by the 18th 
World Medical Association (WMA) General Assembly, 
Helsinki, Finland, June 1964 and amended by the 64th 
WMA General Assembly, Fortaleza, Brazil, October 2013) 
and in accordance with the Dutch Medical Research 
Involving Human Subjects Act (WMO). The study has 
been approved by the Dutch Central Committee on 
Research Concerning Human Subjects (protocol number 
NL51705.000.15). 
Participants will be informed about the study by their 
own rheumatologist. Individuals interested in partic-
ipating will be asked for consent to share their contact 
details with the coordinating investigator. The coordi-
nating investigator will contact the patient and provide 
verbal and written information, including the patient 
letter and informed consent form. These materials have 
been approved by the Dutch Central Committee on 
Research concerning Human Subjects. Participants do 
not have to respond within a set time frame, but at least 2 
weeks ahead of the intended treatment date to allow time 
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Participants can leave the study at any time for any 
reason if they wish to do so without any consequences. 
The investigator can decide to withdraw a participant 
from the study for urgent medical reasons.
After analysis of the data, the results will be dissemi-
nated to the relevant stakeholders, such as rheumatolo-
gists, patients with SSc and digital ulcers and scientists in 
the field of vascular and regenerative medicine. Dissem-
ination will occur through presentations on scientific 
conferences and meetings, and through publication of 
articles in peer-reviewed and patient journals.
After publication of the main study results, data gath-
ered in the trial will be made available. Individual deiden-
tified participant data that underlie the reported results 
will be shared. Other documents that will made available 
are the study protocol, statistical analysis plan and the 
informed consent form. Data will be available immedi-
ately after publication to anyone who wishes to access the 
data. Data will be made available indefinitely and unre-
strictedly at an online location to be determined.
dIsCussIon
In SSc, vascular complications are a major cause of 
morbidity, contribute to end-organ damage and have 
major impact on quality of life and healthcare costs. 
The efficacy and safety of MSC administration has been 
suggested in various conditions, including SSc. Local 
administration of various cell types for digital ulcers and/
or hand stiffness in SSc has been investigated in several 
small uncontrolled studies, in which BM-MNC or adipose 
tissue derived cells were used.35 These studies show that 
locoregional cell administration in the upper limb to 
treat digital ischaemia in SSc is safe and potentially effec-
tive.58 71–76 Recent case reports that explored intravenous 
delivery suggest that administration of MSCs may be a 
worthwhile treatment option in SSc. However, controlled 
trials assessing the intramuscular administration route are 
lacking in SSc. Additionally, allogeneic BM-derived MSC 
therapy is attractive as it may be used as ‘off-the-shelf’ 
available treatment and uses functionally competent MSC 
from healthy donors.
Hence, the MANUS Trial aims to investigate the feasi-
bility, safety and potential clinical effects of intramuscular 
injection of allogeneic BM-MSC in 20 patients with SSc 
with digital ulcers. If the results confirm safety and show 
potential beneficial effects of the intervention regarding 
clinical parameters, a large multicentre RCT with longer 
follow-up will be initiated focusing on efficacy.
Furthermore, the results of this study may provide a 
basis for studies in other groups of patients with vascular 
and/or autoimmune diseases. The extensive vascular 
damage and loss of neovascularisation and vascular regen-
eration makes SSc a relevant ‘model disease’ to study new 
therapeutic regenerative strategies aimed at therapeutic 
neovascularisation.77 If we observe beneficial immuno-
modulatory effects this may provide a basis for further 
studies in SSc but also in other autoimmune diseases.
On the other hand, if we observe no demonstrable 
effect on clinical or laboratory parameters of vasculop-
athy this also has important clinical relevance, as currently 
patients receive (commercial) stem cell therapy for many 
disorders while no adequate well-controlled studies have 
demonstrated safety or efficacy.78 79 The MANUS Trial 
is thus an important step towards evidence-based MSC 
treatment for digital ulcers in SSc.
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